Promoting Competition in Drug Pricing: A Review of Recent Congressional Legislation [Book Review]

Journal of Law, Medicine and Ethics 49 (4):683-687 (2021)
  Copy   BIBTEX

Abstract

Brand-name prescription drug manufacturers use various strategies to extend their market exclusivity periods by delaying generic or biosimilar competition. Recent Congressional legislation has targeted four such tactics. We analyze these proposals and assess their likely effect on competition in the U.S. drug market.

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,423

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

The Importance of the Intent in Predatory Pricing Cases.Raimundas Moisejevas - 2010 - Jurisprudencija: Mokslo darbu žurnalas 122 (4):319-334.
Reauthorization of PDUFA: An Exercise in Post-Market Drug Safety Reform.Peter Chang - 2008 - Journal of Law, Medicine and Ethics 36 (1):196-199.
Pricing Medicine Fairly.Robert C. Hughes - 2020 - Philosophy of Management 19 (4):369-385.

Analytics

Added to PP
2022-04-08

Downloads
8 (#1,291,989)

6 months
7 (#418,426)

Historical graph of downloads
How can I increase my downloads?

Citations of this work

No citations found.

Add more citations

References found in this work

No references found.

Add more references